All In Biotech

Drug Trial Radar · NCT04677972

SPI-1005 for the Treatment of Meniere's Disease

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Aug 2, 2022

Primary completion

Sep 19, 2023

Study completion Jul 25, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial (RCT) with open-label extension study (OLE), of SPI-1005 in adult subjects with definite Meniere's disease with active symptoms within three months preceding study enrollment.

Conditions

  • Meniere Disease
  • Ménière

Interventions

  • EbselenDrug

    Glutathione peroxidase mimetic

  • PlaceboDrug

    Matching placebo containing excipients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse EventsTime frame: 84 days
  2. Change in Low Frequency Hearing Thresholds Measured by Pure Tone AudiometryTime frame: 84 days
  3. Change in Words-in-Noise Test ScoreTime frame: 84 days

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • University of Southern California

    Los Angeles, California

  • House Clinic

    Los Angeles, California

  • Sacramento Ear, Nose, & Throat

    Roseville, California

  • George Washington University

    Washington D.C., District of Columbia

  • ENT and Allergy Associates of Florida

    Boca Raton, Florida

  • Indiana University

    Indianapolis, Indiana

  • Kansas University Medical Center

    Kansas City, Kansas

  • Advanced ENT & Allergy

    Louisville, Kentucky

  • Piedmont Ear, Nose & Throat Associates

    Winston-Salem, North Carolina

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.